Favorable Inductive Remission Rate of Decitabine Combined Chemotherapy on < 60-Years of Age MDS-like AML in the First Course

Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) includes a history of myelodysplasia syndrome (MDS) and no MDS history (30% of AML, MDS-related cytogenetic abnormalities, and multilineage dysplasia) which was called MDS-like AML. We assume that traditional AML therapy combined with decitabine (DAC) may improve the effectiveness. We retrospectively analyzed 98 patients diagnosed as MDS-like AML and evaluated the curative effect and side effects of decitabine combined chemotherapy comparing to standard 3+7 induction protocol.